Cigna (NYSE:CI) Surprises With Q2 CY2026 Sales

Health insurance company Cigna (NYSE:CI) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 6.8% year on year to $71.67 billion. Its non-GAAP profit of $7.78 per share was 2.4% above analysts’ consensus estimates.

Is now the time to buy Cigna? Find out by accessing our full research report, it’s free.

Company Overview

With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group (NYSE:CI) provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans.

Revenue Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Luckily, Cigna’s sales grew at a decent 11.1% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Cigna’s annualized revenue growth of 13.8% over the last two years is above its five-year trend, suggesting its demand recently accelerated.

Cigna also reports its number of customers, which reached 16.68 million in the latest quarter. Over the last two years, Cigna’s customer base averaged 8.1% year-on-year declines. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company’s products and services.

This quarter, Cigna reported year-on-year revenue growth of 6.8%, and its $71.67 billion of revenue exceeded Wall Street’s estimates by 1.3%.

Looking ahead, sell-side analysts expect revenue to grow 3.5% over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and implies its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.

Cigna was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 4.9% was weak for a healthcare business.

Looking at the trend in its profitability, Cigna’s adjusted operating margin decreased by 2 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.2 percentage points. We still like Cigna but would like to see some improvement in the future.

In Q2, Cigna generated an adjusted operating margin profit margin of 2.9%, down 1.4 percentage points year on year. This reduction is quite minuscule and indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Cigna’s remarkable 12% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded.

In Q2, Cigna reported adjusted EPS of $7.78, up from $7.20 in the same quarter last year. This print beat analysts’ estimates by 2.4%. Over the next 12 months, Wall Street expects Cigna’s full-year EPS to stay about the same, moving from $31.48 to $31.53.

Key Takeaways from Cigna’s Q2 Results

It was good to see Cigna narrowly top analysts’ revenue expectations this quarter. Overall, this print had some key positives. The stock remained flat at $294.50 immediately after reporting.

Is Cigna an attractive investment opportunity at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).